Citigroup Forecasts Strong Price Appreciation for ArriVent BioPharma (NASDAQ:AVBP) Stock

ArriVent BioPharma (NASDAQ:AVBP) had its price target lifted by Citigroup from $31.00 to $33.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price objective suggests a potential upside of 38.89% from the company’s current price.

Several other research firms have also recently weighed in on AVBP. HC Wainwright raised their price objective on shares of ArriVent BioPharma from $42.00 to $44.00 and gave the company a “buy” rating in a research report on Friday. Zacks Research raised shares of ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, December 5th. Cantor Fitzgerald started coverage on shares of ArriVent BioPharma in a report on Monday, December 22nd. They issued an “overweight” rating for the company. Truist Financial assumed coverage on shares of ArriVent BioPharma in a research report on Tuesday, November 25th. They issued a “buy” rating and a $43.00 price objective for the company. Finally, BTIG Research began coverage on ArriVent BioPharma in a research report on Wednesday, December 10th. They issued a “buy” rating and a $45.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.44.

ArriVent BioPharma Trading Down 5.9%

NASDAQ AVBP traded down $1.49 during trading hours on Friday, reaching $23.76. 659,620 shares of the company’s stock were exchanged, compared to its average volume of 463,975. The stock has a market cap of $980.81 million, a PE ratio of -5.60 and a beta of 0.99. The firm has a fifty day moving average of $22.17 and a 200-day moving average of $20.89. ArriVent BioPharma has a one year low of $15.47 and a one year high of $27.22.

ArriVent BioPharma (NASDAQ:AVBP) last announced its earnings results on Monday, March 9th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.09. As a group, research analysts forecast that ArriVent BioPharma will post -2.74 EPS for the current year.

Hedge Funds Weigh In On ArriVent BioPharma

Hedge funds have recently added to or reduced their stakes in the stock. Bessemer Group Inc. bought a new position in ArriVent BioPharma during the third quarter worth about $26,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of ArriVent BioPharma by 27.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,006 shares of the company’s stock valued at $40,000 after acquiring an additional 438 shares during the period. Russell Investments Group Ltd. raised its position in shares of ArriVent BioPharma by 9,747.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,068 shares of the company’s stock valued at $38,000 after acquiring an additional 2,047 shares during the period. BNP Paribas Financial Markets boosted its stake in ArriVent BioPharma by 31.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock worth $56,000 after acquiring an additional 609 shares during the last quarter. Finally, Group One Trading LLC acquired a new position in ArriVent BioPharma during the fourth quarter valued at approximately $57,000. Institutional investors and hedge funds own 9.48% of the company’s stock.

Key Headlines Impacting ArriVent BioPharma

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Unusually large call buying: Traders bought ~1,832 call options on Friday (≈321% above typical call volume). Heavy call activity can indicate speculative bullish bets or hedging by sophisticated traders, which may drive short‑term upside interest in the shares.
• Positive Sentiment: HC Wainwright raised its price target from $42 to $44 and maintained a “buy” rating — implying ~83% upside from the cited $24.05 reference price. Analyst optimism and a higher target can attract momentum and institutional interest. Benzinga
• Positive Sentiment: Quarterly EPS beat: AVBP reported (‑$0.78) EPS vs. consensus (‑$0.87), beating by $0.09. An earnings beat for a clinical‑stage biotech reduces short‑term execution risk and can support valuation re‑rating. Earnings Release
• Positive Sentiment: Broker consensus: Coverage summary lists a “Moderate Buy” consensus from brokerages, which reinforces the positive analyst narrative and can support longer‑term inflows. Brokerage Consensus
• Neutral Sentiment: Full‑year 2025 financial results and company update were published (press release). The release provides corporate outlook and financials that investors will parse for cash runway, R&D progress and guidance — important but not an immediate directional catalyst until details are digested. Full Year 2025 Results
• Neutral Sentiment: Short‑interest data reported as zero shares with NaN changes — likely a data anomaly or reporting quirk. This makes short‑interest an unreliable driver currently; absence of meaningful short positions would remove a potential squeeze dynamic.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.